Maxim Group analyst Jason McCarthy maintained a Buy rating on Annovis Bio (ANVS – Research Report) yesterday and set a price target of $26.00. The company's shares closed last Friday at $9.44, close to its 52-week low of $9.23. According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -36.2% and a 9.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group. Annovis Bio has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.
https://www.tipranks.com/news/blurbs/maxim-group-maintains-a-buy-rating-on-annovis-bio-anvs?utm_source=advfn.com&utm_medium=referral
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Mai 2022 bis Jun 2022 Click Here for more Annovis Bio Charts.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Jun 2021 bis Jun 2022 Click Here for more Annovis Bio Charts.